Alert over JAK inhibitor's blood clot risk

The TGA says patients on high doses of tofacitinib need to be warned

Patients on the Janus kinase inhibitor tofacitinib should be monitored, and warned about signs and symptoms of pulmonary embolism, the TGA says.